PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Autolus Therapeutics plc (AUTL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS05280R1005
CUSIP05280R100
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.70B
EPS-$1.20
Revenue (TTM)$1.70M
Gross Profit (TTM)-$130.86M
EBITDA (TTM)-$168.96M
Year Range$1.61 - $7.45
Target Price$10.29
Short %2.26%
Short Ratio2.13

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Autolus Therapeutics plc

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Autolus Therapeutics plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%50.00%100.00%150.00%200.00%NovemberDecember2024FebruaryMarchApril
109.40%
15.73%
AUTL (Autolus Therapeutics plc)
Benchmark (^GSPC)

S&P 500

Returns By Period

Autolus Therapeutics plc had a return of -23.91% year-to-date (YTD) and 172.22% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-23.91%6.12%
1 month-15.81%-1.08%
6 months109.40%15.73%
1 year172.22%22.34%
5 years (annualized)-28.30%11.82%
10 years (annualized)N/A10.53%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-6.52%-0.33%6.33%
2023-27.41%21.03%51.77%50.47%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of AUTL is 90, placing it in the top 10% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of AUTL is 9090
Autolus Therapeutics plc(AUTL)
The Sharpe Ratio Rank of AUTL is 9393Sharpe Ratio Rank
The Sortino Ratio Rank of AUTL is 9090Sortino Ratio Rank
The Omega Ratio Rank of AUTL is 8686Omega Ratio Rank
The Calmar Ratio Rank of AUTL is 9090Calmar Ratio Rank
The Martin Ratio Rank of AUTL is 9292Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Autolus Therapeutics plc (AUTL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AUTL
Sharpe ratio
The chart of Sharpe ratio for AUTL, currently valued at 2.05, compared to the broader market-2.00-1.000.001.002.003.002.05
Sortino ratio
The chart of Sortino ratio for AUTL, currently valued at 2.85, compared to the broader market-4.00-2.000.002.004.006.002.85
Omega ratio
The chart of Omega ratio for AUTL, currently valued at 1.32, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for AUTL, currently valued at 1.69, compared to the broader market0.001.002.003.004.005.001.69
Martin ratio
The chart of Martin ratio for AUTL, currently valued at 10.29, compared to the broader market-10.000.0010.0020.0030.0010.29
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.89, compared to the broader market-2.00-1.000.001.002.003.001.89
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.74, compared to the broader market-4.00-2.000.002.004.006.002.74
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.43, compared to the broader market0.001.002.003.004.005.001.43
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.65, compared to the broader market-10.000.0010.0020.0030.007.65

Sharpe Ratio

The current Autolus Therapeutics plc Sharpe ratio is 2.05. A Sharpe ratio higher than 2.0 is considered very good.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00NovemberDecember2024FebruaryMarchApril
2.05
1.89
AUTL (Autolus Therapeutics plc)
Benchmark (^GSPC)

Dividends

Dividend History


Autolus Therapeutics plc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-89.79%
-3.66%
AUTL (Autolus Therapeutics plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Autolus Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Autolus Therapeutics plc was 96.58%, occurring on Apr 26, 2023. The portfolio has not yet recovered.

The current Autolus Therapeutics plc drawdown is 89.79%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.58%Nov 12, 20181120Apr 26, 2023
-27.36%Sep 11, 201823Oct 11, 201820Nov 8, 201843
-24.83%Jun 27, 201812Jul 13, 201821Aug 13, 201833
-5.65%Aug 20, 20184Aug 23, 201810Sep 7, 201814
-0.82%Aug 14, 20181Aug 14, 20181Aug 15, 20182

Volatility

Volatility Chart

The current Autolus Therapeutics plc volatility is 18.86%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%NovemberDecember2024FebruaryMarchApril
18.86%
3.44%
AUTL (Autolus Therapeutics plc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Autolus Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items